Key Highlights
- Liquidia shares are trading up 5.41% at $58.20 versus a prior close of $55.21.
- Yutrepia net product sales rose 31% from the second quarter to $222.7 million.
- A one-time settlement charge of $389.7 million drove a GAAP net loss of $236.3 million.
- Raymond James upgraded the stock to Strong Buy and lifted its target to $77 from $53.
- Management expects to give 2027 guidance in early January with fourth quarter results.
Liquidia (NASDAQ:LQDA) is trading up 5.41% at $58.20, its fourth straight session of gains after closing up 7.41% at $55.21 on Wednesday. Investors are weighing strong third quarter Yutrepia sales against a large settlement charge. Peer Insmed (NASDAQ:INSM) is trading down 1.85%, so Liquidia is moving against its group.
Yutrepia Sales Keep Climbing
Net product sales of Yutrepia grew 31% from the second quarter to $222.7 million, an increase of about $52 million. Paid patient Demand supplied $212.2 million of that total. It was the fifth consecutive quarter of growth in prescriptions, Revenue and adjusted EBITDA, which reached $140.5 million.
Gross Margin was about 94%, and selling and administrative costs fell from 33% to 26% of revenue. Management put the US prostacyclin market at about $4.9 billion, with roughly 80% of it in pulmonary arterial hypertension.
Settlement Charge Weighs on the Bottom Line
The company booked a one-time charge of $389.7 million tied to the United Therapeutics settlement, of which $380.7 million is payable in cash through April 2027. That drove a GAAP net loss of $236.3 million.
Cash ended the quarter at $396.1 million before settlement payments, up $111.9 million. Management said it needs no Capital raise, is not changing its operating plan and owes no ongoing royalties after the final payment.
Prescription Trends After the Ruling
The label for Yutrepia is now narrowed to pulmonary arterial hypertension, and a competitor letter to prescribers created a brief pause in referrals at select centers. Management said it has since sent corrected communication to prescribers.
Pulmonary arterial hypertension share of prescriptions exceeded 70% in September, and October shipments were the highest since launch. The daily referral rate ran just over 75% of the third quarter rate, which management called a floor. Conversion rates remain above 87%, with about 1,300 prescribers. Existing patients are not required to switch, and management expects no formulary changes.
Analysts Raise Targets
Raymond James upgraded the stock to Strong Buy and lifted its target to $77 from $53, citing a prescription market larger than expected. Needham raised its target to $66, BTIG to $87, Jefferies to $62 and BofA to $54, while Wells Fargo moved to $40 with an Equal Weight rating. The consensus average target is $60.50, only modestly above the current price.
Early January Outlook Sets the Next Test
Whether the rally holds depends on how fast referrals rebuild after the pause. Management expects 2027 guidance in early January with fourth quarter results, and that outlook will show how much of the October floor turns into growth. Investors will also track whether referral rates recover above the 75% level in November and December.
Pipeline work adds longer-term markers. The RE-WARM dose-finding study in Raynaud's phenomenon tied to systemic sclerosis is expected to finish in the first half of 2027, and enrollment in the RE-SPIRE pivotal study of L606 should complete in 2028. Settlement payments of $380.7 million through April 2027 will draw on the $396.1 million cash balance.






Please wait processing your request...